Adenosine preconditions against endothelin-induced constriction of coronary arterioles

D Merkus1, D W Stepp, D W Jones

  • 1Department of Physiology, Medical College of Wisconsin, Milwaukee, Wisconsin 53226, USA. dmerkus@mcw.edu

Insights

Adenosine preconditioning, through A(2) receptors, protects against endothelin-1 induced coronary artery constriction. This vascular preconditioning effect may prevent excessive vasoconstriction during myocardial hypoperfusion.

Area of Science:

  • Cardiovascular Physiology
  • Vascular Biology
  • Pharmacology

Background:

  • Myocardial hypoperfusion increases adenosine and endothelin-1 (ET-1).
  • Adenosine's vasodilatory effect typically outweighs ET-1's vasoconstriction.
  • The interaction between adenosine and ET-1 during preconditioning is not fully understood.

Purpose of the Study:

  • To investigate if adenosine-induced or ischemic preconditioning reduces the vasoconstrictive effect of ET-1.
  • To identify the specific adenosine receptor subtype involved in this protective mechanism.

Main Methods:

  • Coronary arteriolar diameter was measured in vivo using fluorescence microangiography in dogs.
  • Isolated coronary arterioles were used in vitro to assess ET-1 dose-response curves.
  • Adenosine and specific A(1) or A(2) receptor antagonists were administered to evaluate their effects.

Main Results:

  • ET-1 induced significant coronary constriction in vivo.
  • Adenosine preconditioning completely blocked ET-1-induced constriction.
  • Ischemic preconditioning attenuated ET-1-induced constriction.
  • Adenosine preconditioning shifted the ET-1 dose-response curve rightward, an effect blocked by A(2) receptor antagonists but not A(1) antagonists.

Conclusions:

  • Adenosine confers a vascular preconditioning effect against endothelin-1-induced coronary constriction.
  • This protective effect is mediated via the A(2) adenosine receptor.
  • Adenosine's role in preventing excessive coronary constriction may be a novel protective mechanism.

Related Concept Videos

Adrenergic Receptors: ɑ Subtype01:31

Adrenergic Receptors: ɑ Subtype

Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase C—inositol-1,4,5-trisphosphate...
Antihypertensive Drugs: Action of Calcium Channel Blockers01:18

Antihypertensive Drugs: Action of Calcium Channel Blockers

Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...